Novartis AG
- Country
- π¨πSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2011-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 463
- Registration Number
- NCT00477334
- Locations
- πΊπΈ
Perimeter Institute for Clinical Research Inc. ("PICR"), Atlanta, Georgia, United States
πΊπΈMagee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
πΊπΈThe Conant Foundation Quest Diagnostics, San Francisco, California, United States
Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Novartis
- Registration Number
- NCT00477217
- Locations
- π¦πΊ
Novartis Investigative Site, Gordon, Australia
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)
- Conditions
- Osteoarthritis
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1312
- Registration Number
- NCT00476034
- Locations
- πΉπ·
Novartis Investigative Site, Izmir, Turkey
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)
- Conditions
- Osteoarthritis
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 833
- Registration Number
- NCT00475800
- Locations
- π¨π¦
Novartis Investigative Site, Brampton, Ontario, Canada
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
- Conditions
- Choroidal NeovascularizationAge-Related Macular Degeneration
- Interventions
- First Posted Date
- 2007-05-08
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 95
- Registration Number
- NCT00470678
- Locations
- π¨π³
Novartis Investigative Site, LinKou, Taiwan
π¨π³Novartis Investigative site, Taipei, Taiwan
A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 94
- Registration Number
- NCT00468039
- Locations
- πΊπΈ
Diabetes and Glandular Disease Research Associates, San Antonio, Texas, United States
Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder
- First Posted Date
- 2007-04-30
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 644
- Registration Number
- NCT00467402
- Locations
- πΊπΈ
Novartis Investigative Site, West Allis, Wisconsin, United States
Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 35
- Registration Number
- NCT00465985
- Locations
- π«π·
Novartis Investigational Site, Lille Cedex, France
π¬π§Novartis Investigative Site, London, United Kingdom
Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2011-02-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 26
- Registration Number
- NCT00464776
- Locations
- π©π°
Novartis, Gentofte, Denmark
Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old
- Conditions
- Influenza
- Interventions
- Biological: Comparator influenza vaccineBiological: Influenza virus vaccine
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2015-10-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1893
- Registration Number
- NCT00464672
- Locations
- π¦π·
Site 2: C1425AWK, Buenos Aires, Argentina
π¦π·Site 1: X5000BJH, Cordoba, Argentina